Stockreport

Allena Pharmaceuticals Announces Interim Results from Study 206 of Reloxaliase in High Risk Patients with Advanced Oxalate Disorders

Allena Pharmaceuticals, Inc.  (ALNA) 
Last allena pharmaceuticals, inc. earnings: 3/16 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.allenapharma.com/investor-relations
PDF -- Substantial Treatment Effect Observed in Patients with Enteric Hyperoxaluria, Including Robust Reductions in Both Urine and Plasma Oxalate –-- Reloxaliase Well-Tolera [Read more]